<SEC-DOCUMENT>0001193125-23-157841.txt : 20230531
<SEC-HEADER>0001193125-23-157841.hdr.sgml : 20230531
<ACCEPTANCE-DATETIME>20230531161259
ACCESSION NUMBER:		0001193125-23-157841
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230531
DATE AS OF CHANGE:		20230531

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-258564
		FILM NUMBER:		23981130

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d507509dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed Pursuant to Rule 433</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issuer Free Writing
Prospectus dated May&nbsp;31, 2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Relating to Preliminary Prospectus Supplement dated May&nbsp;31, 2023</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Registration Statement No. 333-258564</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g507509g0527034335244.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>NEWS RELEASE </I></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas, May 31, 2023 &#150; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (&#147;<B><I>Lexicon</I></B>&#148;) today announced that it has
commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a
<FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup, Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the underwritten public offering, Lexicon intends to sell shares of its common stock in a private placement to an affiliate
of Invus, L.P., Lexicon&#146;s largest stockholder, pursuant to its preemptive right under Lexicon&#146;s Fifth Amended and Restated Certificate of Incorporation. Lexicon intends to grant the private placement purchaser an option to purchase, on a
pro rata basis, additional shares of common stock to the extent the underwriters exercise their option to purchase additional common stock. Any shares of common stock offered pursuant to the concurrent private placement would not be registered under
the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;). The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon currently intends to use the net proceeds that it will receive from the proposed offering, together with its existing cash and cash equivalents and
short-term investments, to fund the commercial launch of INPEFA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (sotagliflozin). Lexicon expects to use any remaining net proceeds that it will receive from the proposed offering to fund the
continued research and development of its drug candidates and for working capital and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> relating to the proposed offering was filed with the U.S. Securities and Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) on&nbsp;August&nbsp;6, 2021 and declared effective by the SEC on
September&nbsp;14, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-258564).</FONT> A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the
SEC&#146;s website at www.sec.gov. When&nbsp;available, copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717
(Tel: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-831-9146);</FONT></FONT> Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by
<FONT STYLE="white-space:nowrap">e-mail</FONT> at <U>prospectus_department@jefferies.com</U> or by telephone at (877) <FONT STYLE="white-space:nowrap">821-7388;</FONT> or Piper Sandler&nbsp;&amp; Co., Attention: Prospectus Department, 800 Nicollet
Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) <FONT STYLE="white-space:nowrap">747-3924,</FONT> or&nbsp;by email at prospectus@psc.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these
securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lexicon Pharmaceuticals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon is a
biopharmaceutical company with a mission of pioneering medicines that safely and effectively treat disease. Lexicon advanced two of these medicines to market and has additional drug candidates in discovery and clinical and preclinical development in
heart failure, neuropathic pain, diabetes and metabolism and other indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without limitation, statements about the completion and timing of the proposed offering, the use of proceeds from the proposed offering and the grant of the
option to the underwriters and the private placement purchaser to purchase additional shares, are based on management&#146;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including
Lexicon&#146;s ability to meet its capital requirements, successfully commercialize INPEFA in heart failure on the timeline and/or at the prices currently contemplated or at all, conduct preclinical and clinical development and obtain necessary
regulatory approvals of INPEFA (in other indications), LX9211 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#146;s actual results to be materially
different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#147;Risk Factors&#148; in Lexicon&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2023 and other subsequent disclosure documents filed with
the SEC. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Investor Inquiries</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carrie Siragusa </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>csiragusa@lexpharma.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Media Inquiries</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alina Cocuzza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>acocuzza@lexpharma.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Statement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon has filed a registration statement (including a prospectus) with the SEC for the equity offering to which this communication relates. Before
you&nbsp;invest, you should read the preliminary prospectus supplement and the accompanying prospectus in that registration statement and other documents&nbsp;Lexicon has filed with the SEC for more complete information about Lexicon and the equity
offering. You may get these documents for free&nbsp;by visiting EDGAR on the SEC&#146;s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from Citigroup, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Tel:&nbsp;800-831-9146);</FONT></FONT> Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by e-mail at prospectus_department@jefferies.com or by telephone at (877) 821-7388; or Piper Sandler &amp; Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by
telephone at (800) 747-3924, or by email at prospectus@psc.com. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g507509g0527034335244.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g507509g0527034335244.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +D# 2(  A$! Q$!_\0
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M^J]@\TFGVTEPFR=HE,B 8VMCD58H **** "D(# @C(/4&EHH :B)&@1%"JO
M ' ID]M%<JBRKN".LB\]&4Y!J6B@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
